131
views
0
recommends
+1 Recommend
0 collections
    8
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Protein recovery from inclusion bodies of Escherichia coli using mild solubilization process.

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Formation of inclusion bodies in bacterial hosts poses a major challenge for large scale recovery of bioactive proteins. The process of obtaining bioactive protein from inclusion bodies is labor intensive and the yields of recombinant protein are often low. Here we review the developments in the field that are targeted at improving the yield, as well as quality of the recombinant protein by optimizing the individual steps of the process, especially solubilization of the inclusion bodies and refolding of the solubilized protein. Mild solubilization methods have been discussed which are based on the understanding of the fact that protein molecules in inclusion body aggregates have native-like structure. These methods solubilize the inclusion body aggregates while preserving the native-like protein structure. Subsequent protein refolding and purification results in high recovery of bioactive protein. Other parameters which influence the overall recovery of bioactive protein from inclusion bodies have also been discussed. A schematic model describing the utility of mild solubilization methods for high throughput recovery of bioactive protein has also been presented.

          Related collections

          Most cited references126

          • Record: found
          • Abstract: found
          • Article: not found

          Cellular strategies for controlling protein aggregation.

          The aggregation of misfolded proteins is associated with the perturbation of cellular function, ageing and various human disorders. Mounting evidence suggests that protein aggregation is often part of the cellular response to an imbalanced protein homeostasis rather than an unspecific and uncontrolled dead-end pathway. It is a regulated process in cells from bacteria to humans, leading to the deposition of aggregates at specific sites. The sequestration of misfolded proteins in such a way is protective for cell function as it allows for their efficient solubilization and refolding or degradation by components of the protein quality-control network. The organized aggregation of misfolded proteins might also allow their asymmetric distribution to daughter cells during cell division.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            A Consensus Method for the Prediction of ‘Aggregation-Prone’ Peptides in Globular Proteins

            The purpose of this work was to construct a consensus prediction algorithm of ‘aggregation-prone’ peptides in globular proteins, combining existing tools. This allows comparison of the different algorithms and the production of more objective and accurate results. Eleven (11) individual methods are combined and produce AMYLPRED2, a publicly, freely available web tool to academic users (http://biophysics.biol.uoa.gr/AMYLPRED2), for the consensus prediction of amyloidogenic determinants/‘aggregation-prone’ peptides in proteins, from sequence alone. The performance of AMYLPRED2 indicates that it functions better than individual aggregation-prediction algorithms, as perhaps expected. AMYLPRED2 is a useful tool for identifying amyloid-forming regions in proteins that are associated with several conformational diseases, called amyloidoses, such as Altzheimer's, Parkinson's, prion diseases and type II diabetes. It may also be useful for understanding the properties of protein folding and misfolding and for helping to the control of protein aggregation/solubility in biotechnology (recombinant proteins forming bacterial inclusion bodies) and biotherapeutics (monoclonal antibodies and biopharmaceutical proteins).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Aggregation as bacterial inclusion bodies does not imply inactivation of enzymes and fluorescent proteins

              Background Many enzymes of industrial interest are not in the market since they are bio-produced as bacterial inclusion bodies, believed to be biologically inert aggregates of insoluble protein. Results By using two structurally and functionally different model enzymes and two fluorescent proteins we show that physiological aggregation in bacteria might only result in a moderate loss of biological activity and that inclusion bodies can be used in reaction mixtures for efficient catalysis. Conclusion This observation offers promising possibilities for the exploration of inclusion bodies as catalysts for industrial purposes, without any previous protein-refolding step.
                Bookmark

                Author and article information

                Journal
                Microb. Cell Fact.
                Microbial cell factories
                Springer Science and Business Media LLC
                1475-2859
                1475-2859
                Mar 25 2015
                : 14
                Affiliations
                [1 ] Product Development Cell, National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi, 110067, India. anupamsinghsls@gmail.com.
                [2 ] Product Development Cell, National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi, 110067, India. vaibhav@nii.ac.in.
                [3 ] Product Development Cell, National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi, 110067, India. arunkumarupadhyay@gmail.com.
                [4 ] Product Development Cell, National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi, 110067, India. smsingh.79@gmail.com.
                [5 ] Product Development Cell, National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi, 110067, India. amulya@nii.res.in.
                Article
                10.1186/s12934-015-0222-8
                10.1186/s12934-015-0222-8
                4379949
                25889252
                1c65bd50-2b18-409d-97ae-91c89c820d79
                History

                Comments

                Comment on this article